Patent 9315501 was granted and assigned to Incyte on April, 2016 by the United States Patent and Trademark Office.
The present invention relates to bicyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.